A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Participants with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor
Details
Age
Adult
Type of Study
Treatment
Locations
Rocky Mountain Regional VA Medical Center
Principal Investigator
Daniel Bowles, MD
Study ID
Protocol Number: 20-2644
More information available at ClinicalTrials.gov: NCT04590963
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers